New FTC commissioner's potential impact on healthcare

Alvaro Bedoya’s confirmation has restored a Democratic majority on the Federal Trade Commission. Under a Democratic majority, FTC Chair Khan has the ability to continue to further test novel theories of harm in both merger and non-merger matters generally and in healthcare in particular. Additionally, Commissioner Bedoya’s background in privacy and technology could further broaden the scope of both merger and non-merger investigations. We consider the potential scope of these novel theories of harm as applied to healthcare transactions and conduct.

Read the full CPI Antitrust Chronicle article.

Special thanks to summer associate Antonia Mordino for assisting in the preparation of this article.